HIM
MRVI icon

Hillsdale Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Hillsdale Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
+1,682,878
New +$7.27M 0.24% 99

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Hillsdale Investment Management's MRVI Position: Q2 2026 in Review

Hillsdale Investment Management opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 1,682,878 shares worth $10.5M. The stake represents 0.24% of the portfolio and ranks #99 among its holdings.

178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Hillsdale Investment Management held 1,682,878 shares of Maravai LifeSciences worth $10.5M as of Q2 2026.
  • Maravai LifeSciences was a new Hillsdale Investment Management position in Q2 2026.
  • Maravai LifeSciences made up 0.24% of Hillsdale Investment Management's portfolio in Q2 2026, its #99 holding.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.